Drug Trial Radar · NCT02172573
Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Jun 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
315
Actual
Start
Apr 1999
Primary completion
Jul 2000
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jun 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study was to evaluate the efficacy and safety of SND 919 (pramipexole) tablets administered in combination with L-dopa in patients with Parkinson's disease using placebo and bromocriptine tablets as comparators in a double-blind design (phase III comparative study).
Conditions
- Parkinson Disease
Interventions
PramipexoleDrug
BromocriptineDrug
Placebo pramipexoleDrug
Placebo bromocriptineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in total score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living)Time frame: Baseline and week 12
- Change from baseline in total score of UPDRS Part III (Motor Examination)Time frame: Baseline and week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.